Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX-RE trial of RE-01 for non-healing ischemic lower extremity ulcers
jRCT2033260076Phase 2Recruiting
- Sponsor
- ReEir
- Start
- Jun 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RE-01 in lower extremity ulcer, Buerger disease (TAO), systemic sclerosis (SSc) and 4 more, sponsored by ReEir. Primary endpoint: Proportion of subjects who responded by 5 months after baseline. Started Jun 2026; status: recruiting.
02
Drugs
RE-01
03
Conditions
lower extremity ulcerBuerger disease (TAO)systemic sclerosis (SSc)systemic lupus erythematosus (SLE)dermatomyositis (DM)
Beyond the preview
Go deeper on jRCT2033260076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260076.